Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
|Articles|October 1, 2002
- Volume 0 0
October 2002: Rx Image Two
Author(s)Unknown
Advertisement
The technician was very confused with this Rx, so she asked the pharmacist for clarity. After a few guesses, the pharmacist realized that she could not decipher it. She asked the patient if she knew what the doctor prescribed. The patient replied, and then the physician verified what the patient said. What would your guess be?
Click Here For The Answer ----------->
[
Estrostep1 pk
toggle(getObject('exp1048685570_link'), 'exp1048685570');
Articles in this issue
about 24 years ago
Voriconazole (Vfend)about 24 years ago
Pharmacist with Cerebral Palsy Sues for Job Discriminationabout 24 years ago
Almonds Can Cut Cholesterolabout 24 years ago
Interpependence In Health Careabout 24 years ago
Cold and Flu Season Is Hereabout 24 years ago
Drug Diversion in Veterinary Medicineabout 24 years ago
Benefits of Lowering Cholesterol After Heart Attackabout 24 years ago
Fish Oil Plus Statins May Be Effective as Combination Therapyabout 24 years ago
Breast-Feeding May Lower Cholesterol in Adulthoodabout 24 years ago
Red Wine Linked to Increased HDL LevelsAdvertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Community Pharmacists Guide Patients New to Glucose Monitoring
3
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
4
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
5